Oleander Medical Technologies' core offering is the Targeted Osmotic Lysis (TOL) therapy, a novel cancer treatment utilizing a generic drug (digoxin) combined with a pulsed electric field device. This unique combination forces cancer cells to burst, effectively eliminating them while sparing healthy cells. The treatment is designed to be minimally invasive and significantly reduce the side effects associated with conventional cancer therapies.